Redpin Therapeutics is a privately-held, preclinical stage gene therapy company based in New York City.  We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Our approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy.

Pharmaceutical

Redpin Therapeutics

Elma S. Hawkins

Brian McVeigh

David Bleakman

The leadership team at Redpin Therapeutics has a wealth of experience in the biotech industry. The Executive Chairman was previously at Quiet Therapeutics, and the President and CEO was at Lion Biotechnologies. The team also has a Founder and CEO with a background in Viridian Pharmaceuticals, as well as a COO and Vice Chairman with experience in Antigenics. All members of the team have extensive experience in various aspects of the biotech industry, which gives them a unique perspective on how to run a successful company.

Leadership Team

About

Team members